首页> 美国卫生研究院文献>Arthritis Research >Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

【2h】

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

机译：生物仿制药的节省是否可以抵消与剂量增加相关的成本增加？英夫利昔单抗和戈利木单抗治疗类风湿关节炎的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Baseline characteristics of patients initiating golimumab or infliximab and characteristics of their prescribing clinicians

机译：起始戈利木单抗或英夫利昔单抗的患者的基线特征及其处方医生的特征

著录项

期刊名称 Arthritis Research
作者
Jeffrey R. Curtis; Fenglong Xie; Jonathan Kay; Joel D Kallich;
展开▼
作者单位

展开▼
年(卷),期 2019(21),-1
年度 2019
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类外科学;
关键词
Infliximab; Golimumab; Biosimilar; Dose escalation; Rheumatoid arthritis;

机译：英夫利昔单抗;戈利木单抗;生物仿制药;剂量递增;类风湿关节炎;

相似文献

外文文献
中文文献
专利

1. Comparison of Baseline Characteristics of Rheumatoid Arthritis Patients Initiating Therapy with Subcutaneous Golimumab and Infliximab and Intravenous Golimumab: An Analysis from the Prospective, Observational Registry, BioTRAC [J] . Faraawi Rafat, Olszynski Wojciech, Chow Andrew, The Journal of rheumatology . 2016,第6期

机译：皮下注射戈利木单抗，英夫利昔单抗和戈利木单抗静脉治疗的类风湿关节炎患者基线特征的比较：前瞻性，观察性登记，BioTRAC分析
2. Comparison of Baseline Characteristics of Rheumatoid Arthritis Patients Initiating Therapy with Subcutaneous Golimumab and Infliximab and Intravenous Golimumab: An Analysis from the Prospective, Observational Registry, BioTRAC [J] . Faraawi Rafat, Olszynski Wojciech, Chow Andrew, The Journal of rheumatology . 2016,第6期

机译：对皮下吉尔单抗和英夫利昔单抗及静脉内戈尔单抗的类风湿性关节炎患者基线特征的比较：前瞻性，观测登记，Biotrac的分析
3. Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab [J] . Thorne Carter, Boire Gilles, Chow Andrew, The Journal of rheumatology . 2016,第6期

机译：类风湿关节炎患者开始用依那西普，阿达木单抗和英夫利昔单抗进行生物治疗的剂量递增和联合治疗强度的比较
4. COMPARING STATISTICS WITH MACHINE LEARNING MODELS TO PREDICT DOSE INCREASE OF INFLIXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS [C] . Stijn Van Looy, Bert Vander Cruyssen, Bart Wyns, IASTED International Conference on Artificial Intelligence and Soft Computing . 2005

机译：将统计数据与机器学习模型进行比较，以预测类风湿性关节炎患者英夫利昔单抗的剂量增加
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab [O] . Lorie A Ellis, Elisabetta Malangone-Monaco, Helen Varker, 2019

机译：英夫利昔单抗或静脉注射戈利木单抗治疗的类风湿关节炎患者匹配人群的美国现实世界给药模式和直接输注相关费用的比较分析
7. COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB [O] . K. Garces, C. Thorne, G. Boire, 2016

机译：用乙酸盐，Adalimalab或英夫利昔单抗的生物处理患者剂量升级和剂量升级的比较和成本

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

摘要

著录项

相似文献

相关主题

期刊订阅